Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Google Secures Pentagon AI Deal for Classified Projects 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
ST. LOUIS, Feb. 08, 2016 -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 fourth quarter and full year ended December 31, 2015 on Monday, February 22, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis fourth quarter and full year 2015 financial results conference call | ||||||
| When: | Monday, February 22nd at 4:30 p.m. Eastern Time (1:30 p.m. PT) | ||||||
| Dial In Number: | To access the live call, dial 888-417-8465 (US and Canada) or 719-325-2329 (International) and give the participant pass code 4685179. | ||||||
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com | ||||||
| Call Replay: | A replay of the call will be available approximately one hour following the end of the call through 7:30 p.m. ET on February 29, 2016. | ||||||
| Replay Numbers: | 888-203-1112 (US and Canada) | ||||||
| 719-457-0820 (International) | |||||||
| Replay passcode: 4685179 | |||||||
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
Press Contact: Martin Stammer Chief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 [email protected]
